FDA moves toward easing restrictions on certain peptides BioPharma Dive FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York GHK Cu + TB 500 + BPC 157 (BLEND) 70MG Oneday Compounds Why do compounding pharmacists in Canada dispense oral BPC 157? BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with